DBV Technologies SA (DBVT) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$8.82

From 52W high−63.45%

Volume269940.00

Market cap$563.75M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$8.82

From 52W high

−63.45%

Volume

269940.00

Market cap

$563.75M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.4x

P/E (TTM)

—

RSI (14)

26.6

MomentumView details →

1D Return

−0.88%

YTD Return

−53.22%

SummaryUpdated Jun 1, 2026

DBV Technologies S.A. (NASDAQ:DBVT) is a French clinical-stage biopharmaceutical company founded in 2002 and headquartered in Montrouge, France. The company went public on NASDAQ in October 2014 and specializes in developing epicutaneous immunotherapy treatments, which deliver therapeutic compounds through the skin rather than through injections or oral medications. DBV Technologies is primarily focused on developing treatments for food allergies, with its lead product candidate being Viaskin Peanut for treating peanut allergies in children and toddlers.

Ask drillr about DBV Technologies SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−109.63%

ROA (TTM)

−78.78%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+43.75%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−41.67%

EBITDA YoY

−45.28%

MomentumView details →

1D Return

−0.88%

YTD Return

−53.22%

1Y Return

−45.01%

RSI (14)

26.6

vs 50D SMA

−27.21%

vs 200D SMA

−48.13%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

3.72x

Quick Ratio

3.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.14

EPS Surprise

−14.32%

Beats (12Q)

6/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

−71.38%

Rev Surprise

2.83%

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−175.85M

Op. CF (TTM)

−199.79M

Next earningsOct 28, 2026 →

Latest newsMore news →

DBV Technologies submitted a Biologics License Application to the U.S. FDA for its VIASKIN Peanut Patch for children aged 4-7 years, requesting Priority Review.20d ago

DBV Technologies sold approximately $50 million of American Depositary Shares through its At-The-Market program on Nasdaq to RA Capital Management, with Citizens JMP Securities acting as sales agent.81d ago

Similar companies

Phathom Pharmaceuticals, Inc.PHAT Climb Bio, Inc.CLYM CorMedix Inc.CRMD Shattuck Labs, Inc.STTK Bright Minds Biosciences Inc.DRUG Puma Biotechnology, Inc.PBYI Find similar companies →

Latest newsMore news →

DBV Technologies submitted a Biologics License Application to the U.S. FDA for its VIASKIN Peanut Patch for children aged 4-7 years, requesting Priority Review.20d ago DBV Technologies sold approximately $50 million of American Depositary Shares through its At-The-Market program on Nasdaq to RA Capital Management, with Citizens JMP Securities acting as sales agent.81d ago